Serin Istemi, Orhan Bagnu, Sonmez Derya, Cinli Tahir Alper, Goze Hasan, Serin Huriye, Gulesir Begum, Yokus Osman
Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Org. Nafiz GURMAN Cad., Samatya, Fatih, Istanbul, Istanbul, 34098 Turkey.
Department of Medical Biochemistry, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey.
Leuk Res Rep. 2022 Feb 15;17:100293. doi: 10.1016/j.lrr.2022.100293. eCollection 2022.
We aimed to examine the efficiency for prediction of prognosis and response in non-APL AML cases of the "Samatya-predicting score". A total of 213 patients diagnosed between January 2010-December 2020 were examined. Of the 158 patients included in the study, the median value of risk score was determined as 2,5. The sensitivity for mortality was 88% and the specificity was 42%. In terms of being non-responder to induction therapy, the sensitivity was 90,1%, the specificity was 25,3%. OS was shorter in those with high risk scores. This study makes an important contribution to the literature in terms of creating a different perspective to predict prognosis in AML.
我们旨在检验“萨马提亚预测评分”对非急性早幼粒细胞白血病（APL）的急性髓系白血病（AML）病例预后和反应的预测效率。对2010年1月至2020年12月期间诊断的213例患者进行了检查。在纳入研究的158例患者中，风险评分的中位数确定为2.5。死亡率的敏感性为88%，特异性为42%。就诱导治疗无反应而言，敏感性为90.1%，特异性为25.3%。高风险评分患者的总生存期较短。本研究在为AML预后预测提供不同视角方面对文献做出了重要贡献。
